Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice

Objectives Anti-TIF-1 gamma autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1 gamma detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have eme...

Descripción completa

Detalles Bibliográficos
Autores: Mariscal, A, Milan, M, Baucells, A, Martinez, MA, Guillen, AG, Trallero-Araguas, E, Alvarado-Cardenas, M, Martinez-Martinez, L, Alserawan, L, Franco-Leyva, T, Sanz-Martinez, MT, Vinas-Gimenez, L, Corominas, H, Juarez, C, Castellvi, I, Selva-O'Callaghan, A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p5046
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5046
Access Level:acceso abierto
Palabra clave:dermatomyositis
cancer
autoantibody
diagnosis
immunoassay
id ES_2d85b6d2fcce299e91c784c4db162a5f
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p5046
network_acronym_str ES
network_name_str España
repository_id_str
spelling Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical PracticeMariscal, AMilan, MBaucells, AMartinez, MAGuillen, AGTrallero-Araguas, EAlvarado-Cardenas, MMartinez-Martinez, LAlserawan, LFranco-Leyva, TSanz-Martinez, MTVinas-Gimenez, LCorominas, HJuarez, CCastellvi, ISelva-O'Callaghan, AdermatomyositiscancerautoantibodydiagnosisimmunoassayObjectives Anti-TIF-1 gamma autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1 gamma detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1 gamma. Methods We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebron Hospital (Barcelona, Spain) tested for anti-TIF-1 gamma autoantibodies using the Euroline profile and an in-house immunoblot assay. Results A total of 27 anti-TIF-1 gamma were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen's kappa 0.3163. Expected prevalence of anti-TIF-1 gamma autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1 gamma autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p<0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1 gamma antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline). Conclusion We recommend using a second validated method to confirm Euroline-detected anti-TIF-1 gamma antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1 gamma antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method.FRONTIERS MEDIA SA2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5046Frontiers in ImmunologyISSN: 16643224reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p50462026-06-14T12:41:47Z
dc.title.none.fl_str_mv Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
title Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
spellingShingle Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
Mariscal, A
dermatomyositis
cancer
autoantibody
diagnosis
immunoassay
title_short Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
title_full Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
title_fullStr Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
title_full_unstemmed Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
title_sort Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
dc.creator.none.fl_str_mv Mariscal, A
Milan, M
Baucells, A
Martinez, MA
Guillen, AG
Trallero-Araguas, E
Alvarado-Cardenas, M
Martinez-Martinez, L
Alserawan, L
Franco-Leyva, T
Sanz-Martinez, MT
Vinas-Gimenez, L
Corominas, H
Juarez, C
Castellvi, I
Selva-O'Callaghan, A
author Mariscal, A
author_facet Mariscal, A
Milan, M
Baucells, A
Martinez, MA
Guillen, AG
Trallero-Araguas, E
Alvarado-Cardenas, M
Martinez-Martinez, L
Alserawan, L
Franco-Leyva, T
Sanz-Martinez, MT
Vinas-Gimenez, L
Corominas, H
Juarez, C
Castellvi, I
Selva-O'Callaghan, A
author_role author
author2 Milan, M
Baucells, A
Martinez, MA
Guillen, AG
Trallero-Araguas, E
Alvarado-Cardenas, M
Martinez-Martinez, L
Alserawan, L
Franco-Leyva, T
Sanz-Martinez, MT
Vinas-Gimenez, L
Corominas, H
Juarez, C
Castellvi, I
Selva-O'Callaghan, A
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv dermatomyositis
cancer
autoantibody
diagnosis
immunoassay
topic dermatomyositis
cancer
autoantibody
diagnosis
immunoassay
description Objectives Anti-TIF-1 gamma autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1 gamma detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1 gamma. Methods We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebron Hospital (Barcelona, Spain) tested for anti-TIF-1 gamma autoantibodies using the Euroline profile and an in-house immunoblot assay. Results A total of 27 anti-TIF-1 gamma were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen's kappa 0.3163. Expected prevalence of anti-TIF-1 gamma autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1 gamma autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p<0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1 gamma antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline). Conclusion We recommend using a second validated method to confirm Euroline-detected anti-TIF-1 gamma antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1 gamma antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5046
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5046
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv FRONTIERS MEDIA SA
publisher.none.fl_str_mv FRONTIERS MEDIA SA
dc.source.none.fl_str_mv Frontiers in Immunology
ISSN: 16643224
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405326417068032
score 15,81155

Similares en LA Referencia